Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ROCK1 | Q13464 | 1/20 | 0.50 |
| ▸ | EGFR | P00533 | 3/20 | 0.49 |
| ▸ | ERBB3 | P21860 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.48 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.48 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.48 |
| ▸ | HPGD | P15428 | 1/20 | 0.48 |
| ▸ | RXFP1 | Q9HBX9 | 1/20 | 0.48 |
| ▸ | MPL | P40238 | 4/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.46 |
| ▸ | RAB9A | P51151 | 1/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | CLK4 | Q9HAZ1 | 1/20 | 0.45 |
| ▸ | LCK | P06239 | 2/20 | 0.45 |
| ▸ | TP53 | P04637 | 1/20 | 0.44 |
| ▸ | FGFR3 | P22607 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4873959 | 0.86 | AURKA (0.50) | EGFRERBB3MPLNPC1RAB9A | |
| SCHEMBL4873164 | 0.84 | MPL (0.55) | ROCK1EGFRERBB3MEN1KMT2A | |
| SCHEMBL4874060 | 0.81 | NPC1 (0.57) | ROCK1EGFRERBB3MEN1KMT2A | |
| SCHEMBL11317380 | 0.76 | MEN1 (0.55) | EGFRERBB3MEN1KMT2ANPC1 | |
| SCHEMBL4879483 | 0.75 | EGFR (0.49) | ROCK1EGFRERBB3MEN1KMT2A | |
| SCHEMBL4868204 | 0.74 | SMN1; SMN2 (0.50) | ROCK1EGFRERBB3MPLRAB9A | |
| SCHEMBL4871031 | 0.74 | ROCK1 (0.62) | ROCK1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL13955869 | 0.74 | KMT2A (0.72) | ROCK1MEN1KMT2AKDM4EHPGD | |
| SCHEMBL4109227 | 0.73 | USP2 (0.72) | CYP1A2CLK4 | |
| SCHEMBL4109262 | 0.73 | CYP1A2 (0.53) | ROCK1EGFRERBB3MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | REITER LAWRENCE A | 2008-03-27 | — | — | US | disclosed |
| EP-1794156-A2 | TROMBOPOIETIN RECEPTOR AGONISTS | Pfizer Products Incorporated (US) | 2007-06-13 | — | — | EP | disclosed |
| WO-2006033005-A2 | THROMBOPOIETIN RECEPTOR AGONISTS | PFIZER PRODUCTS INC. (US) | 2006-03-30 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080076771-A1 | Thrombopoietin Receptor Agonists | MPL, THPO, TBXA2R | ROCK1 2928/4885EGFR 996/4885ERBB3 1245/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.